原发性胶质母细胞瘤的分子与细胞瘤内异质性:临床与转化意义
本文综述胶质母细胞瘤(GBM)瘤内异质性(ITH)的分子与表型研究进展,聚焦胶质瘤干细胞、分子特征和代谢改变对治疗抵抗与复发的影响,探讨其转化意义以改善临床结局。
要点
- GBM含自我更新的胶质瘤干细胞,驱动肿瘤起始、异质性、治疗抵抗和复发。
- 瘤内异质性是GBM临床结局不良的主要因素之一。
- 分子特征与代谢改变是潜在转化靶点,但尚需临床验证。
核心结论
- GBM瘤内异质性(分子与表型)是治疗抵抗和不良临床结局的重要驱动因素。
研究设计与样本
- 综述类文章,总结GBM分子与表型特征特别是瘤内异质性的近期研究进展。
主要发现
- GBM含自我更新、致瘤的胶质瘤干细胞,参与肿瘤起始、异质性、治疗抵抗和复发。
临床怎么用
- 需关注瘤内异质性对GBM治疗抵抗和复发的影响,探索分子与代谢特征的转化应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glioblastoma (GBM), the most common primary malignant brain tumor in adults, is associated with significant morbidity and mortality despite maximal safe resection followed by chemo- and radiotherapy. GBMs contain self-renewing, tumorigenic glioma stem cells that contribute to tumor initiation, heterogeneity, therapeutic resistance, and recurrence. Intratumoral heterogeneity (ITH) of GBMs is also a major contributing factor to poor clinical outcomes associated with these high-grade glial tumors. Herein, the authors summarize recent discoveries and advances in the molecular and phenotypic characterization of GBMs with particular focus on ITH. In so doing, they attempt to highlight recent advances in molecular signatures/properties and metabolic alterations in an effort to clarify translational implications that may ultimately improve clinical outcomes.
引用
- Bernstock JD, Mooney JH, Ilyas A, et al. Molecular and cellular intratumoral heterogeneity in primary glioblastoma: clinical and translational implications. J Neurosurg. 2019. PMID: 31443071. doi:10.3171/2019.5.JNS19364
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。